Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/valsartan versus valsartan for blood pressure control and interdialytic weight gain in ESRD patients on hemodialysis
IRCT20251014067624N2Phase 3Recruiting
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sacubitril + valsartan and valsartan in end-stage kidney disease (ESKD) and hypertension (HTN) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Blood pressure levels, Interdialytic weight gain and 2 more. Started Jun 2026; status: recruiting.
02
Drugs
sacubitril + valsartanvalsartan
03
Conditions
end-stage kidney disease (ESKD)hypertension (HTN)
Beyond the preview
Go deeper on IRCT20251014067624N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251014067624N2.